Skip to content
MARKETS / NASDAQ / IART
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · LARGE CAP

Integra Lifesciences Holdings Corp. IART

18 fiscal years on record · USD · FY2025 reported · SEC filings only
$1.6B
▲ 1.5% YoY
$-516.5M
$-31.1M
▼ 224.4% YoY
In brief

What this company does

Integra LifeSciences Holdings Corporation manufactures and sells medical technologies and products. As of December 31, 2025, the company had 4,427 regular full and part time employees. It maintains manufacturing and research facilities in California, Maryland, Massachusetts, New Jersey, Ohio, Puerto Rico, Tennessee, Utah, France, Germany, Ireland, Israel and Switzerland. The company is organized into two reportable business segments, Codman Specialty Surgical and Tissue Technologies. The CSS segment, which accounted for approximately 70% of total revenue, consists of technologies and instrumentation used for specialties including neurosurgery, neurocritical care and otolaryngology, also known as ear, nose and throat. Integra LifeSciences Holdings Corporation was founded in 1989.

Written from the business description in INTEGRA LIFESCIENCES HOLDINGS CORP's annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.

Growth
USD 1.6B
Revenue, FY2025 · full 18-year series below
Revenue $B Net income $B
FY2025 · Revenue 1.6 · Net income -0.5
0.8B1.6B-0.2B-0.4B2008201120142017202020232025
Compound annual growth
+1.6%
+3.6%
+6.4%
+5.5%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +3.6% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−32 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -30.2% · Net -31.6%
5%10%15%-10%-20%-30%2008201120142017202020232025
ROE
FY2025 · ROE -39.9%
5%10%-10%-20%-30%2008201120142017202020232025

Each USD of equity lost 40 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -31.1
100M200M-20M2008201120142017202020232025
Net buybacks $M Dividends $M
FY2025 · Dividends — · Net buybacks -0.7
100M200M-200M20082010201220182020202220242025

Total assetsUSD 3.6B
EquityUSD 1.0B
CashUSD 235.0M
Gross debtUSD 726.6M
Net debtUSD 491.5M
Current ratio2.54×

Net debt stands at 47% of equity.

The 18-year record
18 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023202220212020201920182017201620152014201320122011201020092008
Revenue $B1.61.61.51.61.51.41.51.51.21.00.90.80.70.80.80.70.70.7
Operating income $B−0.50.00.10.20.20.20.10.10.00.10.10.10.00.10.10.10.10.0
EBITDA $B−0.40.10.20.30.20.20.10.20.10.20.10.10.10.10.10.10.10.1
Income tax $B−0.0−0.00.00.00.0−0.00.0−0.0−0.10.00.10.0−0.00.00.00.00.0−0.0
Net income $B−0.5−0.00.10.20.20.10.10.10.10.1−0.00.0−0.00.00.00.10.10.0
Free cash flow $B−0.00.00.10.20.30.20.20.10.10.10.10.00.0−0.00.10.10.10.1
EPS, diluted $−6.74−0.090.842.161.981.570.580.720.820.94−0.050.52−0.741.440.952.171.740.96
Dividend / sh $··················
Payout %··················
ROE %−39.9−0.44.010.310.69.13.65.27.29.4−0.55.0−3.68.25.613.912.57.4

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 77 reconciliationsAUDITED

Reconciled in 18 of 19 fiscal years. 7 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2008

Share this section

Download image